Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 2
2015 12
2016 7
2017 8
2018 15
2019 15
2020 15
2021 15
2022 12
2023 17
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Loss of ZNRF3/RNF43 Unleashes EGFR in Cancer.
Yue F, Ku AT, Stevens PD, Michalski MN, Jiang W, Tu J, Shi Z, Dou Y, Wang Y, Feng XH, Hostetter G, Wu X, Huang S, Shroyer NF, Zhang B, Williams BO, Liu Q, Lin X, Li Y. Yue F, et al. bioRxiv [Preprint]. 2024 Jan 11:2024.01.10.574969. doi: 10.1101/2024.01.10.574969. bioRxiv. 2024. PMID: 38260423 Free PMC article. Preprint.
Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer.
Zhao N, Kabotyanski EB, Saltzman AB, Malovannaya A, Yuan X, Reineke LC, Lieu N, Gao Y, Pedroza DA, Calderon SJ, Smith AJ, Hamor C, Safari K, Savage S, Zhang B, Zhou J, Solis LM, Hilsenbeck SG, Fan C, Perou CM, Rosen JM. Zhao N, et al. J Clin Invest. 2023 Dec 15;133(24):e172503. doi: 10.1172/JCI172503. J Clin Invest. 2023. PMID: 37874652 Free PMC article.
Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer.
Zhao N, Kabotyanski EB, Saltzman AB, Malovannaya A, Yuan X, Reineke LC, Lieu N, Gao Y, Pedroza DA, Calderon SJ, Smith AJ, Hamor C, Safari K, Savage S, Zhang B, Zhou J, Solis LM, Hilsenbeck SG, Fan C, Perou CM, Rosen JM. Zhao N, et al. bioRxiv [Preprint]. 2023 Sep 28:2023.09.28.559973. doi: 10.1101/2023.09.28.559973. bioRxiv. 2023. PMID: 37808840 Free PMC article. Updated. Preprint.
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors.
Lv X, Lu X, Cao J, Luo Q, Ding Y, Peng F, Pataer A, Lu D, Han D, Malmberg E, Chan DW, Wang X, Savage SR, Mao S, Yu J, Peng F, Yan L, Meng H, Maneix L, Han Y, Chen Y, Yao W, Chang EC, Catic A, Lin X, Miles G, Huang P, Sun Z, Burt B, Wang H, Wang J, Yao QC, Zhang B, Roth JA, O'Malley BW, Ellis MJ, Rimawi MF, Ying H, Chen X. Lv X, et al. Science. 2023 Sep 8;381(6662):eabn4180. doi: 10.1126/science.abn4180. Epub 2023 Sep 8. Science. 2023. PMID: 37676964 Free PMC article.
Multiomics analyses reveal DARS1-AS1/YBX1-controlled posttranscriptional circuits promoting glioblastoma tumorigenesis/radioresistance.
Zheng C, Wei Y, Zhang Q, Sun M, Wang Y, Hou J, Zhang P, Lv X, Su D, Jiang Y, Gumin J, Sahni N, Hu B, Wang W, Chen X, McGrail DJ, Zhang C, Huang S, Xu H, Chen J, Lang FF, Hu J, Chen Y. Zheng C, et al. Sci Adv. 2023 Aug 4;9(31):eadf3984. doi: 10.1126/sciadv.adf3984. Epub 2023 Aug 4. Sci Adv. 2023. PMID: 37540752 Free PMC article.
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment.
Kim BJ, Zheng ZY, Lei JT, Holt MV, Chen A, Peng J, Fandino D, Singh P, Kennedy H, Dou Y, Chica-Parrado MDR, Bikorimana E, Ye D, Wang Y, Hanker AB, Mohamed N, Hilsenbeck SG, Lim B, Asirvatham JR, Sreekumar A, Zhang B, Miles G, Anurag M, Ellis MJ, Chang EC. Kim BJ, et al. Cancer Res Commun. 2023 Jul 26;3(7):1366-1377. doi: 10.1158/2767-9764.CRC-23-0044. eCollection 2023 Jul. Cancer Res Commun. 2023. PMID: 37501682 Free PMC article.
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer.
Veeraraghavan J, Gutierrez C, De Angelis C, Davis R, Wang T, Pascual T, Selenica P, Sanchez K, Nitta H, Kapadia M, Pavlick AC, Galvan P, Rexer B, Forero-Torres A, Nanda R, Storniolo AM, Krop IE, Goetz MP, Nangia JR, Wolff AC, Weigelt B, Reis-Filho JS, Hilsenbeck SG, Prat A, Osborne CK, Schiff R, Rimawi MF. Veeraraghavan J, et al. Clin Cancer Res. 2023 Aug 15;29(16):3101-3109. doi: 10.1158/1078-0432.CCR-22-3753. Clin Cancer Res. 2023. PMID: 37195235 Free PMC article.
101 results